Alnylam and Mayo Clinic Partner to Develop RNAi Parkinson s Drug

Oct 30, 2003

NEW YORK, Oct. 30 - Alnylam, of Cambridge, Mass., has formed a collaboration with researchers at the Mayo Clinic in Rochester, Minn., to develop an RNA interference-based drug that suppresses genes over-expressed in people with Parkinson's disease, the company said today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

From Relatives to Suspects

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

Family Ties

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

This Week in Science

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

Time to Kick Back With Some Golf

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.

Main menu